{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:14:45Z","timestamp":1694582085865},"reference-count":34,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T00:00:00Z","timestamp":1236211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>Patients who have had malignant melanoma are at an increased risk of developing a second primary melanoma compared with the general population risk of developing a first melanoma. Many of these second primary melanomas occur at a similar anatomic site as the first lesion. Determining whether a second lesion is indeed a separate primary vs. a metastasis or locoregional recurrence can be very difficult histologically. We report the case of a patient who developed a second melanoma, 2 years after the initial diagnosis, within 3 cm of the site of the original lesion. Because of distinct histomorphologic features, the second lesion was favored to be a separate primary. However, because of the nearly identical anatomic location, molecular testing for loss of heterozygosity and <jats:italic>BRAF<\/jats:italic> mutation was performed to help further make this distinction. The first lesion was found to have loss of heterozygosity and a <jats:italic>BRAF<\/jats:italic> mutation that were not present in the second lesion. While these tests cannot elucidate the true molecular origin of these lesions, they provide a useful clinical tool to assess whether a second lesion should be treated as a recurrence or as a separate lesion with unique biologic potential.<\/jats:p>","DOI":"10.1111\/j.1600-0560.2008.01226.x","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T08:51:21Z","timestamp":1236243081000},"page":"74-79","source":"Crossref","is-referenced-by-count":3,"title":["Two cutaneous malignant melanomas at the same anatomic site: a case report with molecular evaluation"],"prefix":"10.1111","volume":"36","author":[{"given":"James T.","family":"Edinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Radfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drazen M.","family":"Jukic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,17]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0705-0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.8.1013"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.13.1647"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q"},{"key":"e_1_2_5_6_2","first-page":"330","article-title":"Multiple primary melanoma: incidence and risk factors in 283 patients","volume":"113","author":"Slingluff CL","year":"1993","journal-title":"Surgery"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.110878"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.4.433"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199411000-00008"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930915)72:6<1909::AID-CNCR2820720619>3.0.CO;2-S"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247327"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-199108000-00011"},{"key":"e_1_2_5_13_2","first-page":"533","article-title":"Epidermotropic malignant melanoma: the distinction between metastatic and new primary lesions in the skin","volume":"27","author":"Jackson R","year":"1984","journal-title":"Can J Surg"},{"key":"e_1_2_5_14_2","first-page":"225","article-title":"Epidermotropic metastatic malignant melanoma","volume":"55","author":"Mehregan DA","year":"1995","journal-title":"Cutis"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200201000-00010"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.515"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb03159.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(01)00819-4"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1177\/000313480106701020","article-title":"Desmoplastic melanoma","volume":"67","author":"Payne WG","year":"2001","journal-title":"Am Surg"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-1578(10)60663-0"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019606-200309000-00006"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000087421.44975.1C"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.015800"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(02)00651-9"},{"key":"e_1_2_5_25_2","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt K","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_2_5_27_2","first-page":"3883","article-title":"BRAF oncogenic mutations correlate with progression rather than initiation of human melanomas","volume":"63","author":"Dong J","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22523.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050120"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q"},{"key":"e_1_2_5_31_2","first-page":"1727","article-title":"A genetic explanation of Slaughter\u2019s concept of field cancerization: evidence and clinical implications","volume":"63","author":"Braakhuis BJ","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-9877(02)00240-2"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.41"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1939"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5465"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0560.2008.01226.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0560.2008.01226.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:46:01Z","timestamp":1694558761000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0560.2008.01226.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,17]]},"references-count":34,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1600-0560.2008.01226.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0560.2008.01226.x","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,17]]}}}